Our mission is to generate novel molecular insights that transform drug development and healthcare globally.
Did you know that 60% of therapeutics don’t work and over 92% of clinical trials fail? The losses are staggering, from patients urgently needing treatment, to drug development companies losing billions. Inoviv is changing the drug development landscape with our novel proteomic solutions. We are the first in the field to provide a highly accurate and precise analysis of clinical trial samples in an extremely efficient way, accelerating drug development and reducing risk for pharma companies around the world.
We are a VC backed business at an exciting point in our growth trajectory, having successfully tripled our revenues each year over the last 2 years. We are on a journey to triple again in 2025 and currently in the process of raising series A funding.